Tags

Type your tag names separated by a space and hit enter

Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas.
J Dermatol 2019JD

Abstract

The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions. The aim of this study is to investigate the safety concerns regarding intralesional injection of lauromacrogol combined with triamcinolone for IH and to study its effect on infant growth and development. A total of 1039 IH patients who were subjected to intralesional injection of lauromacrogol combined with triamcinolone in the Plastic Surgery Department of Shandong Provincial Hospital between 1 January 2015 and 31 May 2018 were enrolled in this study. When the dose of lauromacrogol and triamcinolone was less than 3.5 and 2.0 mg/kg respectively, no serious side-effects were observed. The adverse event rate reported was 7.7%. Among the 405 patients not subjected to propranolol before the last injection, the study included three modes of treatment response: regression (82.7%), stabilization (13.8%) and failure (3.5%). By comparing height and weight to the reference standards and also by comparisons between the same-sex groups, our results confirmed that there was no significant effect on children's height and weight, regardless of whether the injection therapy was combined with oral propranolol at the appropriate dose and with more than 4-week intervals. Intralesional injection of lauromacrogol combined with triamcinolone in the treatment of IH was highly safe and effective.

Authors+Show Affiliations

Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.Department of Burn and Plastic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31270853

Citation

Chai, Yimeng, et al. "Safety of Intralesional Injection of Lauromacrogol Combined With Triamcinolone for Infantile Hemangiomas." The Journal of Dermatology, 2019.
Chai Y, Zhou Z, Song J, et al. Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. J Dermatol. 2019.
Chai, Y., Zhou, Z., Song, J., Lv, R., Xu, G., Bi, J., ... Huo, R. (2019). Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. The Journal of Dermatology, doi:10.1111/1346-8138.14992.
Chai Y, et al. Safety of Intralesional Injection of Lauromacrogol Combined With Triamcinolone for Infantile Hemangiomas. J Dermatol. 2019 Jul 4; PubMed PMID: 31270853.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety of intralesional injection of lauromacrogol combined with triamcinolone for infantile hemangiomas. AU - Chai,Yimeng, AU - Zhou,Zifu, AU - Song,Jiayin, AU - Lv,Renrong, AU - Xu,Guangqi, AU - Bi,Jianhai, AU - Li,Xueqing, AU - Li,Zhiyu, AU - Huo,Ran, Y1 - 2019/07/04/ PY - 2019/03/31/received PY - 2019/05/23/accepted PY - 2019/7/5/entrez KW - hemangioma KW - intralesional KW - lauromacrogol KW - safety KW - triamcinolone JF - The Journal of dermatology JO - J. Dermatol. N2 - The efficacy of lauromacrogol injection therapy and intralesional triamcinolone for infantile hemangiomas (IH) has been well documented recently, but with an increase in serious or rare adverse reactions. The aim of this study is to investigate the safety concerns regarding intralesional injection of lauromacrogol combined with triamcinolone for IH and to study its effect on infant growth and development. A total of 1039 IH patients who were subjected to intralesional injection of lauromacrogol combined with triamcinolone in the Plastic Surgery Department of Shandong Provincial Hospital between 1 January 2015 and 31 May 2018 were enrolled in this study. When the dose of lauromacrogol and triamcinolone was less than 3.5 and 2.0 mg/kg respectively, no serious side-effects were observed. The adverse event rate reported was 7.7%. Among the 405 patients not subjected to propranolol before the last injection, the study included three modes of treatment response: regression (82.7%), stabilization (13.8%) and failure (3.5%). By comparing height and weight to the reference standards and also by comparisons between the same-sex groups, our results confirmed that there was no significant effect on children's height and weight, regardless of whether the injection therapy was combined with oral propranolol at the appropriate dose and with more than 4-week intervals. Intralesional injection of lauromacrogol combined with triamcinolone in the treatment of IH was highly safe and effective. SN - 1346-8138 UR - https://www.unboundmedicine.com/medline/citation/31270853/Safety_of_intralesional_injection_of_lauromacrogol_combined_with_triamcinolone_for_infantile_hemangiomas L2 - https://doi.org/10.1111/1346-8138.14992 DB - PRIME DP - Unbound Medicine ER -